


Life Settlement Assets PLC – Ordinary Share A

Investment Objective

The company’s investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Estimated Performance

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	Roll. 12M
Est. Performance (%) 2022	-1.59%	-1.05%	0.16%	-0.29%	1.00%	1.93%	0.06%	-0.60%					-0.44%	3.60%



Commentary

Investment Terms

1.5% Management Fee

Estimated NAV (USD)

108 817 053

NAV/Share

2.1839

Life expectancy dropped across the United States in 2020, but nowhere did it drop more than in New York. A report from the National Centre for Health Statistics examines how that decline varied from state to state. It found that eight states and Washington, D.C., saw life expectancy fall by more than two years from 2019 to 2020. New York saw the sharpest decline: a drop of three years from 80.7 years to just 77.7. This was primarily due to the effects of the Covid-19 pandemic as well as “diseases of despair” such as drug overdoses. New York has one of the higher life expectancies in the US but the stark evidence illustrates the remarkable toll that 2020 took on a country that was already seeing an extended and previously unprecedented decline in life expectancy.

The Share Class is reporting a performance of -0.60% for the month of August. Three HIV maturities were registered, contributing a total Death Benefit of \$0.3M; two maturities of \$1.1M were registered in the non-HIV segment this month.

Number Of Policies	Net Death Benefits (USD)	Matured Policies YTD	Maturities YTD (USD)
4 281	426 574 620	70	19 909 479

Trust Investment Manager Acheron Capital Ltd.

Administrator Compagnie Européenne de Révision


Auditor BDO UK LLP

Company Secretary ISCA Administration Services Limited


ISIN Ticker GB00BF1Q4B05 LSAA

Info life@acheroncapital.com +44 207 258 5990


Distribution by Age




Distribution by Death Benefit Amount⁽¹⁾ (USD)




Distribution by Gender




Distribution by Insurance Company



Distribution by Issue Date⁽²⁾ (Yrs)



Maturities Since Inception




(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.

(2)Distribution by issue dates reflects the time since the life insurance policy was issued.

Source of Data: Acheron Capital Ltd unless otherwise stated.


Historical Maturity



Maturities August 2022

Number of policies matured in August 2022	5
Corresponding number of insured	5
Total death benefit in August 2022 (US\$)	1 465 248
Valuation of Matured policies in Book (US\$)	510 366

Notification of Maturity



Premiums Situation (US\$) ⁽¹⁾

Servicers Premiums Projection for the next 12 months	\$ 13.4M
Mortality Adjusted Premiums Projection for the next 12 months	\$ 12.8M
Estimated COI Net of Mortality for the next 12 months	\$ 12.5M

Top 10 Coverage

Insured	Face (millions)	Total Face (millions)	Age (ALB)	Expiration Age*
1	5.9/1.2	7.1	97	100/120
2	1.8/2.3/1.5	5.8	79	121/100/100
3	5.5	5.5	97	100
4	1.6/0.9/0.6/0.4/0.2	3.7	94	100/100/100/100/100
5	3.5	3.5	95	100
6	3.4	3.4	81	100
7	1.5/1.0/0.3	2.8	91	100/100/100
8	2.8	2.8	91	100
9	2.8	2.8	100	100
10	1.6/1.1	2.7	100	120/120

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.